Ovarian cancer tends to be resistant to hormone therapy, even when it should theoretically respond. Wistar Institute ...

Ovarian cancer, often a \"silent killer,\" is the 8th most common cancer in women globally and the third in India. Early ...

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ...

Ovarian cancer, often called the “silent killer,” continues to be one of the most dangerous threats to women’s health, ...

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Germline pathogenic variants (gPVs) occur in a subset of patients with ovarian cancer, with the highest prevalence among those with Ashkenazi Jewish ancestry, followed by Asian and Hispanic patients, ...

Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing ...

COIMBATORE: Under the National Health Mission (NHM), a group of surgical oncologists from eight medical college hospitals ...

First-line PARP inhibitor maintenance after platinum chemotherapy reduces progression risk in certain patients with ovarian ...

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.